SIR 2024
Interventional Oncology
Hiroshi Kodama, MD, PhD (he/him/his)
Associate Professor
Department of Radiology, Hyogo Medical University, Japan
Financial relationships: Full list of relationships is listed on the CME information page.
Motonori Takahagi, MD
Assistant Professor
Hyogo Medical University, Japan
Disclosure information not submitted.
Junichi Taniguchi, MD
Assistant Professor
Hyogo Medical University, Japan
Disclosure information not submitted.
atsushi ogasawara, MD, PhD
Assistant Professor
Hyogo Medical University, Japan
Disclosure information not submitted.
yasukazu kako, MD, PhD
Associate Professor
Hyogo Medical University, Japan
Disclosure information not submitted.
Haruyuki Takaki, MD, PhD
Associate Professor
Department of Radiology, Hyogo College of Medicine, Japan
Disclosure information not submitted.
Koichiro Yamakado, MD, PhD (he/him/his)
Professor
Department of Radiology, Hyogo Medical University, Japan
Financial relationships: Full list of relationships is listed on the CME information page.
To retrospectively evaluate the safety and clinical utility of radiofrequency ablation (RFA) for malignant pleural mesothelioma (MPM).
Materials and Methods:
Eight consecutive patients who underwent RFA for recurrent MPM were included between July 2019 and March 2023. All were male, with a median age of 67 years (range, 54-77 years). Eight patients (100%, 8/8) and six patients (75.0%, 6/8) had histories of systemic therapy and surgical treatment, respectively. Five patients (62.5%, 5/8) had multiple tumors (range, 2-6 tumors), and a total of 17 tumors (median tumor diameter, 2.1cm; range, 1.0-7.0cm) were treated in 16 sessions. Local tumor control, survival, and complications were assessed. Local tumor progression and survival rates were calculated using the Kaplan-Meier method. Complications were assessed using the Society of Interventional Radiology classification.
Results:
During the median follow-up period of 41 months (range, 6-66 months), local recurrence was observed in one tumor (5.9%, 1/17), and the local tumor progression rate was 6.7% at both 1- and 3-year. Distant metastasis occurred after RFA in 50.0% (4/8) of the patients, and they were treated with chemotherapy or immune checkpoint inhibitors. One patient died (12.5%, 1/8), and the cause of death was duodenal perforation during the treatment of esophageal carcinoma, 66 months after RFA. The overall survival rate was 100% at both 1- and 3-year intervals. Major and minor complication was seen in 6.3% (1/16) and 6.3% (1/16). These complications were a skin ulcer and retroperitoneal hematoma, respectively.
Conclusion: RFA was safe and useful for the treatment of recurrent MPM.